The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 with more on the horizon (e.g., ND-0612, AP-CD/LD, IPX-203), two new rescue therapies for “off” periods will be available in 2019 (i.e., Inbrija, APL-130277), and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B-001, HP-3000). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales in the PD market. However, given the cost-sensitivity of PD patients and widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.

Questions Answered:

  • What will be the impact of forthcoming levodopa reformulations? Will they alter the PDtreatment paradigm, or be sidelined by access hurdles and/or physician resistance?
  • What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?
  • How will neurologists differentiate among current and next-generation levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 28 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 27 drugs; Phase III: 5 drugs; preregistration: 2 drugs. Coverage of select preclinical and Phase I products.

Market forecast features: Ten-year, annualized, drug-level sales and patient share of key PD therapies through 2027, segmented by brands/generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, UCB, US WorldMeds, Zambon Pharma.

Key drugs: levodopa, amantadine, apomorphine, AP-CD/LD, APL-130277, Duodopa/Duopa, entacapone, Gocovri, HP-3000, IPX-203, ND-0612, Neupro, Nouriast, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B-001, rasagiline, ropinirole, Rytary/Numient, selegiline, Trerief, Xadago.


Related Reports

Parkinson's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more a...

View Details

Parkinson's Disease - Unmet Need - Detailed, Expanded Analysis: Psychosis In PD (US/FR/DEU/UK)

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patie...

View Details

Parkinson's Disease | Disease Landscape and Forecast | G7 | 2019

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two new re...

View Details